Transient Ischemic Attack

Clinical Trial Finder

Many patients who experience transient ischemic attacks (TIAs) are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Predictive Score for the Ischemic Etiology of a Transient Visual Disturbances (VASCO)

Condition:   Vision Disorders
Intervention:   Other: Clinical, ophthalmological and neurological evaluation
Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild
Recruiting - verified June 2015

Real-Life Evidence on Stroke Prevention in SPAF

Condition:   Atrial Fibrillation (Prevention of Stroke)
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists
Sponsors:   Bayer;   Janssen, LP
Active, not recruiting - verified July 2015

Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study

Condition:   Stroke
Intervention:  
Sponsors:   Xuanwu Hospital, Beijing;   The First Affiliated Hospital of Shanxi Medical University;   Liaocheng Brains Hospital;   Tianjin Huanhu Hospital;   Baotou City Central Hospital;   First Hospital of Jilin University;   First Affiliated Hospital of Harbin Medical University;   First Hospital of China Medical University;   LanZhou University;   First Affiliated Hospital of Xinjiang Medical University;   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School;   The First Affiliated Hospital of Soochow University;   Anhui Provincial Hospital;   Guangdong Provincial Hospital of Traditional Chinese Medicine;   Zhuhai  People's Hospital;   Fujian Provincial Hospital;   Mianyang Central Hospital;   The Second Affiliated Hospital of Kunming Medical University;   Brains Hospital of Hunan Province;   Henan Provincial Hospital;   Luoyang Central Hospital Affiliated to Zhengzhou University;   National Health and Family Planning Commission Stroke Prevention Engineering Committee
Recruiting - verified July 2015

Patient and Provider Assessment of Lipid Management Registry

Conditions:   Hyperlipidemia;   Hypercholesterolemia;   Cardiovascular Disease;   Diabetes;   Chronic Kidney Disease (CKD);   Hypertension;   Smoking;   Myocardial Infarction (MI);   Unstable Angina;   Angina;   Coronary Artery Disease (CAD);   Stroke;   Transient Ischemic Attack (TIA);   Carotid Stenosis;   Peripheral Arterial Disease;   Atherosclerosis;   Claudication
Intervention:  
Sponsors:   Duke University;   Regeneron Pharmaceuticals;   Sanofi
Recruiting - verified June 2015

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)

Condition:   Stroke
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin (Acetylsalicylic acid, BAY1019036);   Other: Rivaroxaban-Placebo;   Other: Aspirin-Placebo
Sponsors:   Bayer;   Janssen, LP;   Hamilton Health Sciences Cooperation, Population Health Research Institute
Recruiting - verified July 2015

Hispanic Secondary Stroke Prevention Initiative

Condition:   Stroke
Interventions:   Behavioral: Community Health Worker (CHW) home visits, coaching phone calls, group sessions .;   Other: usual care and health education brochures every 4 months.
Sponsors:   University of Miami;   National Institute on Minority Health and Health Disparities (NIMHD)
Recruiting - verified July 2015

Ethnicity and Onset of Cardiovascular Disease: A CALIBER Study

Conditions:   Abdominal Aortic Aneurysm;   Coronary Heart Disease;   Sudden Cardiac Death;   Intracerebral Haemorrhage;   Heart Failure;   Ischemic Stroke;   Myocardial Infarction;   Stroke;   Peripheral Arterial Disease;   Stable Angina Pectoris;   Subarachnoid Haemorrhage;   Transient Ischemic Attack;   Unstable Angina;   Cardiac Arrest
Intervention:  
Sponsors:   University College, London;   Wellcome Trust;   National Institute for Health Research, United Kingdom;   London School of Hygiene and Tropical Medicine
Active, not recruiting - verified July 2015

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

Conditions:   Ischemic Stroke;   Transient Ischemic Attack
Interventions:   Drug: Rivaroxaban;   Drug: Warfarin
Sponsors:   Asan Medical Center;   Bayer
Recruiting - verified July 2015

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Completed - verified July 2015

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Condition:   Sickle Cell Disease
Interventions:   Drug: Prasugrel;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Daiichi Sankyo Inc.
Active, not recruiting - verified June 2015

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition:   Crohn's Disease
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Recruiting - verified July 2015

TomVasc - Vascular Effects of Tomato Extract

Conditions:   Ischemic Heart Disease;   Transient Ischemic Attack;   Stroke;   Peripheral Vascular Disease
Interventions:   Dietary Supplement: Ateronon;   Dietary Supplement: Placebo
Sponsors:   Cambridge University Hospitals NHS Foundation Trust;   Cambridge Theranostics Ltd
Completed - verified July 2012

Get CardioSmart

You're Invited